Literature DB >> 23942842

Assessment of pathologically diagnosed patients with Castleman's disease associated with diffuse parenchymal lung involvement using the diagnostic criteria for IgG4-related disease.

Takaaki Ogoshi1, Takashi Kido, Kazuhiro Yatera, Keishi Oda, Toshinori Kawanami, Hiroshi Ishimoto, Noriho Sakamoto, Arisa Sano, Chiharu Yoshii, Shohei Shimajiri, Hiroshi Mukae.   

Abstract

BACKGROUND: IgG4-related disease (IgG4RD) is a recently recognized disease entity. Differentiating IgG4RD from plasma cell type Castleman's disease (PCD) is important but also difficult using only pathological findings. In addition, little is known about the association between these two diseases with diffuse parenchymal lung involvement.
METHODS: We analyzed the serum IgG4 levels and the ratio of IgG4/IgG-positive plasmacytes in the lung and lymph node specimens of eight patients previously pathologically diagnosed of PCD with diffuse parenchymal lung involvement (DL-PCD). We also compared the clinical and laboratory findings observed in these patients.
RESULTS: Six of the eight patients exhibited abundant IgG4-positive plasmacytes in the lung and lymph node tissues and elevated serum IgG4 levels, thereby fulfilling the diagnostic criteria of IgG4RD with DL (DL-IgG4RD) in addition to having obstructive phlebitis and massive lymphoplasmacytic infiltration with fibrosis. However, three of these six patients exhibited higher levels of serum interleukin-6 and were still diagnosed with DL-PCD. Accordingly, three of these eight patients were considered as IgG4RD with DL (DL-IgG4RD), and the other five patients were ultimately given a diagnosis of DL-PCD. These two diseases have different characteristics in terms of age, symptoms, serum levels of C-reactive protein, and IgA, complicating allergic disorders, response to corticosteroids, and prognosis.
CONCLUSIONS: This is the first report to show a high prevalence of DL-IgG4RD in DL-PCD patients, although additional large investigations are necessary. Clinical and laboratory findings are important for distinguishing between these two diseases in other organs, as previously described.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23942842     DOI: 10.1007/s00408-013-9497-x

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  32 in total

1.  Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders.

Authors:  Y Masaki; L Dong; N Kurose; K Kitagawa; Y Morikawa; M Yamamoto; H Takahashi; Y Shinomura; K Imai; T Saeki; A Azumi; S Nakada; E Sugiyama; S Matsui; T Origuchi; S Nishiyama; I Nishimori; T Nojima; K Yamada; M Kawano; Y Zen; M Kaneko; K Miyazaki; K Tsubota; K Eguchi; K Tomoda; T Sawaki; T Kawanami; M Tanaka; T Fukushima; S Sugai; H Umehara
Journal:  Ann Rheum Dis       Date:  2008-08-13       Impact factor: 19.103

2.  Pulmonary manifestations of immunoglobulin G4-related sclerosing disease.

Authors:  J H Ryu; H Sekiguchi; E S Yi
Journal:  Eur Respir J       Date:  2011-06-30       Impact factor: 16.671

3.  Elevated IgG4 levels in a case with multicentric Castleman's disease.

Authors:  F Ishida; K Kitano; H Kobayashi; H Saito; K Kiyosawa
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

4.  Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders.

Authors:  Johanna D Strehl; Arndt Hartmann; Abbas Agaimy
Journal:  J Clin Pathol       Date:  2011-01-12       Impact factor: 3.411

5.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

Authors:  J T Beck; S M Hsu; J Wijdenes; R Bataille; B Klein; D Vesole; K Hayden; S Jagannath; B Barlogie
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

6.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Authors:  G Frizzera; B A Peterson; E D Bayrd; A Goldman
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

7.  Lymphadenopathy of IgG4-related sclerosing disease.

Authors:  Wah Cheuk; Hunter K L Yuen; Stephenie Y Y Chu; Edmond K W Chiu; L K Lam; John K C Chan
Journal:  Am J Surg Pathol       Date:  2008-05       Impact factor: 6.394

8.  Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: report of 6 and 12 cases with similar histopathology.

Authors:  Bijayee Shrestha; Hiroshi Sekiguchi; Thomas V Colby; Paolo Graziano; Marie-Christine Aubry; Thomas C Smyrk; Andrew L Feldman; Lynn D Cornell; Jay H Ryu; Suresh T Chari; Amylou C Dueck; Eunhee S Yi
Journal:  Am J Surg Pathol       Date:  2009-10       Impact factor: 6.394

9.  Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis.

Authors:  Yoh Zen; Takahiko Fujii; Kenichi Harada; Mitsuhiro Kawano; Kazunori Yamada; Masayuki Takahira; Yasuni Nakanuma
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

10.  Characteristic findings in images of extra-pancreatic lesions associated with autoimmune pancreatitis.

Authors:  Yasunari Fujinaga; Masumi Kadoya; Shigeyuki Kawa; Hideaki Hamano; Kazuhiko Ueda; Mitsuhiro Momose; Satoshi Kawakami; Sachie Yamazaki; Tomoko Hatta; Yukiko Sugiyama
Journal:  Eur J Radiol       Date:  2009-07-05       Impact factor: 3.528

View more
  12 in total

Review 1.  IgG4-related disease involving polyserous effusions with elevated serum interleukin-6 levels: a case report and literature review.

Authors:  Xiang Tong; Min Bai; Weiya Wang; Qingbing Han; Panwen Tian; Hong Fan
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

2.  Clinical characteristics of a concurrent condition of IgG4-RD and Castleman's disease.

Authors:  Xia Zhang; Panpan Zhang; Linyi Peng; Yunyun Fei; Wei Zhang; Ruie Feng; Wen Zhang
Journal:  Clin Rheumatol       Date:  2018-06-14       Impact factor: 2.980

3.  Immunohistochemical analysis of IgA expression differentiates IgG4-related disease from plasma cell-type Castleman disease.

Authors:  Akihiro Manabe; Takuro Igawa; Mai Takeuchi; Yuka Gion; Tadashi Yoshino; Yasuharu Sato
Journal:  Med Mol Morphol       Date:  2016-07-20       Impact factor: 2.309

4.  Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease.

Authors:  Mitsuhiro Akiyama; Hidekata Yasuoka; Kunihiro Yamaoka; Katsuya Suzuki; Yuko Kaneko; Harumi Kondo; Yoshiaki Kassai; Keiko Koga; Takahiro Miyazaki; Rimpei Morita; Akihiko Yoshimura; Tsutomu Takeuchi
Journal:  Arthritis Res Ther       Date:  2016-07-13       Impact factor: 5.156

Review 5.  Castleman Disease: A Rare Condition with Endocrine Manifestations.

Authors:  Carmen E Cervantes; Ricardo Correa
Journal:  Cureus       Date:  2015-11-17

6.  Distinct features distinguishing IgG4-related disease from multicentric Castleman's disease.

Authors:  Takanori Sasaki; Mitsuhiro Akiyama; Yuko Kaneko; Takehiko Mori; Hidekata Yasuoka; Katsuya Suzuki; Kunihiro Yamaoka; Shinichiro Okamoto; Tsutomu Takeuchi
Journal:  RMD Open       Date:  2017-07-18

Review 7.  Polymyositis with elevated serum IgG4 levels and abundant IgG4+ plasma cell infiltration: A case report and literature review.

Authors:  Ryusuke Anan; Mitsuhiro Akiyama; Yuko Kaneko; Jun Kikuchi; Kazuko Suzuki; Shiro Matsubara; Tsutomu Takeuchi
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

8.  Idiopathic multicentric Castleman's disease: a clinicopathologic study in comparison with IgG4-related disease.

Authors:  Kyoko Otani; Dai Inoue; Kohei Fujikura; Takahiro Komori; Shiho Abe-Suzuki; Takuma Tajiri; Tomoo Itoh; Yoh Zen
Journal:  Oncotarget       Date:  2018-01-09

9.  Overlap of IgG4-related Disease and Multicentric Castleman's Disease in a Patient with Skin Lesions.

Authors:  Hiroki Mochizuki; Manako Kato; Takakazu Higuchi; Ryosuke Koyamada; Satoru Arai; Sadamu Okada; Hikaru Eto
Journal:  Intern Med       Date:  2017-05-01       Impact factor: 1.271

10.  In vitro IL-6/IL-6R Trans-Signaling in Fibroblasts Releases Cytokines That May Be Linked to the Pathogenesis of IgG4-Related Disease.

Authors:  Ji Zongfei; Chen Rongyi; Cui Xiaomeng; Ma Lili; Ma Lingying; Kong Xiufang; Dai Xiaomin; Zhang Zhuojun; Chen Huiyong; Sun Ying; Jiang Lindi
Journal:  Front Immunol       Date:  2020-07-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.